Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.695 USD | +2.07% | +3.31% | -46.33% |
Apr. 26 | Adherium Seeks to Raise AU$8.4 Million Via Placement, Entitlement Offer; Shares Fall 24% | MT |
Apr. 18 | EHealth Reaffirms 2024 Guidance | MT |
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.17 for the 2024 fiscal year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Multiline Insurance & Brokers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-46.33% | 134M | C- | ||
-4.06% | 60.9B | C | ||
+5.71% | 52.12B | B- | ||
+4.59% | 25.81B | C+ | ||
+17.07% | 23.63B | C | ||
+25.12% | 9.33B | - | ||
+17.57% | 6.29B | - | ||
+2.59% | 2B | C+ | ||
+13.70% | 1.8B | C- | ||
-21.94% | 1.49B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EHTH Stock
- Ratings eHealth, Inc.